- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Avita Medical Ltd(RCEL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RCEL
11/18/2026: RCEL (1-star) is a SELL. SELL for 3 days. Simulated Profits (100.26%). Updated daily EoD!
Avita Medical Ltd is a medical device and regenerative medicine company centered on its proprietary RECELL point-of-care skin-harvesting platform. The company's core strengths include high gross margins, expanding hospital account penetration, and favorable recent CMS reimbursement updates. Its primary growth story revolves around label expansions into new indications like vitiligo and the commercial scaling of complementary wound care products. Key risks involve ongoing path-to-profitability execution, intense competition in advanced wound care, and product concentration. The stock suits growth-oriented investors willing to monitor regulatory adoption, sales force productivity, and financial cash-flow milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Avita Medical exhibits rapid double-digit revenue expansion driven by an innovative regenerative medicine platform. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience strong upward momentum during periods of positive earnings surprises and upgraded guidance. |
| Value investor | Weak fit | The company is a commercial-stage growth enterprise currently generating net losses rather than traditional value earnings. |
| Dividend investor | Weak fit | Avita Medical pays no dividends, reinvesting all cash flow into commercial scaling and product development. |
| Low-risk investor | Weak fit | High equity volatility and ongoing path-to-profitability dynamics expose investors to significant clinical and execution risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotechnology and medical device stocks frequently experience sharp price swings based on sentiment and earnings reports. |
| Valuation risk | Medium / high | Valuations heavily discount future growth expectations, leaving little room for commercial execution missteps. |
| Competition risk (advanced wound care and biological matrix competition) | Medium | Well-capitalized medical device giants compete aggressively for hospital budges and wound-care market share. |
| Business quality | Medium / high | High gross margins and proprietary technology demonstrate strong underlying product appeal, balanced by historical net losses. |
| Dividend income | Low / none | No dividend is paid or anticipated in the near term as capital is retained for growth. |
| Execution risk | Medium / high | Future financial health depends heavily on successfully scaling the sales force and expanding clinical adoption. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 499.72M USD | Price to earnings Ratio - | 1Y Target Price 20.67 |
Price to earnings Ratio - | 1Y Target Price 20.67 | ||
Volume (30-day avg) 537.7K shares | Beta 2.01 | 52 Weeks Range 3.22 - 18.43 | Updated Date 11/18/2026 |
52 Weeks Range 3.22 - 18.43 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 50.0%
- Active BUY / eligible
- 4 / 8
- 30-Day BUY Count Change
- +2
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -15.87% | Avg. Invested days 32 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| RECELL Systems & Disposables | Sales of the automated enzyme and processing devices alongside single-use disposable kits consumed during each procedure. | Revenue is generated through a razor-and-blade model where device placements drive recurring sales of single-use procedural kits. |
| Complementary Wound Care Products | Commercial distribution of advanced extracellular matrices and dressings like Cohealyx and PermeaDerm. | Expands wallet share within existing hospital accounts by offering a broader suite of wound healing solutions. |
| Geographic Markets | Commercial operations spanning the United States, Japan, Europe, and Australia. | Primarily concentrated in the U.S. market with growing international contributions as regulatory clearances expand. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 10.29 | Enterprise Value 517.97M | Price to Sales(TTM) 5.9 |
Enterprise Value 517.97M | Price to Sales(TTM) 5.9 | ||
Enterprise Value to Revenue 6.12 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 31.69M | Shares Floating 30.96M |
Shares Outstanding 31.69M | Shares Floating 30.96M | ||
Percent Insiders 1.49 | Percent Institutions 28.98 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

